Literature DB >> 11369064

Characterizing the phenomenon of radiation recall dermatitis.

R Camidge1, A Price.   

Abstract

Radiation recall represents the 'recalling' of an effect similar in appearance to that of an acute radiation reaction in a previously irradiated field. The recall is triggered by the administration of certain drugs days to years after the exposure to ionizing radiation. This review focuses almost exclusively on the skin manifestations of radiation recall to assemble the largest data base upon which to discuss this rare phenomenon. No absolute radiation dose threshold is apparent, but rather an interplay between dose and time before drug exposure seems to affect both the risk and speed of onset of recall. Recall usually occurs on first exposure to a particular recall-triggering drug. The skin reaction develops within minutes to days. The time to develop the reaction may be slightly longer for oral than intravenously administered drugs reflecting their bioavailability. Most drugs associated with recall are cytotoxics, but several other drugs may elicit the phenomenon. Individuals exposed to a number of potentially recall-triggering drugs reveal the marked drug specificity characteristic of the phenomenon. Skin reactions usually settle within a few days of stopping the triggering drug. The role of steroids or anti-histamines in affecting resolution is unclear. Drug rechallenge tends to produce either only a mild recurrence or no recurrence of recall. Steroids or dose reduction may favour uneventful rechallenge. A number of aetiological hypotheses on radiation recall exist. Using the available evidence these hypotheses are critically reviewed and a novel hypothesis based on radiation affecting local cutaneous immunological responses proposed.

Entities:  

Mesh:

Year:  2001        PMID: 11369064     DOI: 10.1016/s0167-8140(01)00328-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  57 in total

1.  Radiation recall dermatitis with azithromycin.

Authors:  O Vujovic
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

2.  Radiation-recall myositis presenting as low-back pain (2010: 4b).

Authors:  Geert Heirwegh; Eveline Bruyeer; Marleen Renard; Anne Uyttebroeck; Philippe Demaerel
Journal:  Eur Radiol       Date:  2010-06-08       Impact factor: 5.315

Review 3.  [Antineoplastic drug-induced extravasation].

Authors:  Maike de Wit
Journal:  Med Klin (Munich)       Date:  2010-11

4.  Vemurafenib and cutaneous adverse events--report of five cases.

Authors:  Giselle de Barros Silva; Adriana Pessoa Mendes; Mariana Petaccia de Macedo; Clóvis Antônio Lopes Pinto; Ivana Lameiras Gibbons; João Pedreira Duprat Neto
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

5.  Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review.

Authors:  Jin Ge; Vivek Verma; Andrew Hollander; Corey Langer; Charles B Simone
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  Radiation recall dermatitis.

Authors:  Claudio Guarneri; Biagio Guarneri
Journal:  CMAJ       Date:  2009-12-21       Impact factor: 8.262

7.  Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment.

Authors:  Jiyoung Rhee; Gwi Eon Kim; Chang Hyun Lee; Jung-Mi Kwon; Sang-Hoon Han; Young Suk Kim; Woo-Kun Kim
Journal:  Radiat Oncol J       Date:  2014-12-30

8.  Radiation recall dermatitis due to gemcitabine does not suggest the need to discontinue chemotherapy.

Authors:  Michael Lock; Kevin Sinclair; Stephen Welch; Jawaid Younus; Mohammad Salim
Journal:  Oncol Lett       Date:  2010-10-05       Impact factor: 2.967

9.  Case report of cold-weather-induced radiation recall dermatitis after chemoradiotherapy with cisplatin.

Authors:  Isabelle Kindts; Karin Stellamans; Michiel Bonny; Nikie Planckaert; Laurence Goethals
Journal:  Strahlenther Onkol       Date:  2014-04-04       Impact factor: 3.621

10.  Radiation recall reaction induced by adjuvant trastuzumab (herceptin).

Authors:  Caroline Chung; David Stuart; Mira Keyes
Journal:  Case Rep Med       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.